Sutura Therapeutics is currently focussed on a ‘holistic’ program to address the pathologic drivers that underpin the changes that occur in Duchenne muscular dystrophy.
Our first program will restore dystrophin protein expression with cardiac tissue of non-ambulant Duchenne muscular dystrophy patients. Other current pipelines programs will seek to improve the other pathological drivers and be suitable for all the Duchenne muscular dystrophy population.
Our Holistic Promise:
“We are a patient orientated company that understands the complexity of the all disease manifestations that occur in Duchenne muscular dystrophy. We are striving to provide ‘all-stage’ disease modifying therapeutics to enhance the quality of life for the community and appreciate a multimodal strategy needs to be adopted. Our enhanced gene medicine delivery platform seeks to address these unmet clinical needs.”